Malignant neoplasm of stomach
Elevation Oncology Discontinues Lead Drug and Cuts Workforce
EO-3021, Claudin 18.2 ADC, Phase 1 trial, gastric cancer, layoffs, strategic options
Leap Therapeutics’ Stock Plummets Following Disappointing DKK1 Antibody Results in Gastric Cancer Trials
Leap Therapeutics, DKK1 Antibody, Gastric Cancer, Clinical Trials, Stock Performance
Astellas Secures FDA Approval for Vyloy, a First-in-Class Claudin-Targeted Therapy for Gastric Cancers
Astellas, Vyloy, FDA Approval, Claudin 18.2, Gastric Cancer, Gastroesophageal Junction Cancer, HER2-negative, Zolbetuximab
FDA Panel Recommends Limiting Immunotherapy Access for Stomach and Esophageal Cancer Patients Based on PD-L1 Expression
FDA, Immunotherapy, Stomach Cancer, Esophageal Cancer, PD-L1 Expression, Keytruda, Opdivo, Tevimbra
FDA Advisory Panel Rejects PD-1 Inhibitors for Gastric and Esophageal Cancers with Low PD-L1 Expression
FDA, PD-1 inhibitors, gastric cancer, esophageal cancer, PD-L1 expression, biomarker, oncology, drug approval
Astellas’ Vyloy (Zolbetuximab) Receives EU Approval for Advanced Gastric and Gastroesophageal Junction Cancer Treatment
Astellas, Vyloy, Zolbetuximab, EU Approval, Gastric Cancer, Gastroesophageal Junction Cancer, Claudin 18.2, Targeted Therapy
Zanidatamab Demonstrates Promising 30-Month Survival Rate in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma
Zanidatamab, HER2-positive, metastatic gastroesophageal adenocarcinoma, bispecific antibody, survival rate, gastric cancer, oncology.
HUTCHMED Withdraws Fruquintinib Application for Second-Line Gastric Cancer Treatment in China
HUTCHMED, fruquintinib, gastric cancer, second-line treatment, China, NDA withdrawal